Onconetix Inc (ONCO) - Total Assets
Based on the latest financial reports, Onconetix Inc (ONCO) holds total assets worth $14.83 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Onconetix Inc - Total Assets Trend (2019–2025)
This chart illustrates how Onconetix Inc's total assets have evolved over time, based on quarterly financial data. Also see ONCO stock market capitalisation for the company's overall valuation and market capitalisation.
Onconetix Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Onconetix Inc's total assets of $14.83 Million consist of 24.3% current assets and 75.7% non-current assets. Review Onconetix Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.9% |
| Accounts Receivable | $296.87K | 1.2% |
| Inventory | $149.96K | 0.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $18.55 Million | 74.4% |
Asset Composition Trend (2019–2025)
This chart illustrates how Onconetix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Onconetix Inc (ONCO) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Onconetix Inc's current assets represent 24.3% of total assets in 2025, a decrease from 99.6% in 2019.
- Cash Position: Cash and equivalents constituted 20.9% of total assets in 2025, down from 99.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 74.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 74.4% of total assets.
Onconetix Inc Competitors by Total Assets
Key competitors of Onconetix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Onconetix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 0.17 | 3.86 |
| Quick Ratio | 1.37 | 0.16 | 3.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.26 Million | $-11.62 Million | $2.27 Million |
Onconetix Inc - Advanced Valuation Insights
This section examines the relationship between Onconetix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.10 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -11.5% |
| Total Assets | $24.93 Million |
| Market Capitalization | $730.29K USD |
Valuation Analysis
Below Book Valuation: The market values Onconetix Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Onconetix Inc's assets decreased by 11.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Onconetix Inc (2019–2025)
The table below shows the annual total assets of Onconetix Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.93 Million | -11.55% |
| 2024-12-31 | $28.18 Million | -67.80% |
| 2023-12-31 | $87.52 Million | +232.64% |
| 2022-12-31 | $26.31 Million | +752.93% |
| 2021-12-31 | $3.08 Million | -35.90% |
| 2020-12-31 | $4.81 Million | -20.87% |
| 2019-12-31 | $6.08 Million | -- |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other … Read more